|Cancer||Cell death||Cell cycle||Cytoskeleton||Exo/endocytosis||Differentiation||Division||Organelles||Signalling||Stem cells||Trafficking|
Cell Biology International (2009) 33, 119124 (Printed in Great Britain)
Effects of Survivin on cell proliferation and apoptosis in MG-63 cells in vitro
Xinjun Lianga1, Mingxu Dab1, Zhiqiang Zhuanga, Weiguang Wua, Zhuang Wua, Yanfeng Wua and Huiyong Shena*
aDepartment of Orthopaedics, Sun-Yat-Sen Memorial Hospital, Sun-Yat-Sen University, 107 West Yanjiang Road, Guangzhou 510120, PR China
bDepartment of General Surgery, Gansu Provincial Hospital, 160 Donggang West Road, Lanzhou 730000, PR China
Osteosarcoma is the most frequent primary malignant tumor of the skeleton and occurs mainly in children and adolescent. The prognosis of osteosarcoma is very poor due to its aggressive and no effective treatment. This study is the first to investigate the anti-cancer effects of antisense pEGFP-C1-Survivin on human osteosarcoma cells. It was shown in our results that Survivin blockaded could significantly induce apoptosis and inhibit the invasive of osteosarcoma cells line MG-63. The effects were probably produced by the decreased expression of Survivin induced by antisense pEGFP-C1-Survivin which was examined by RT-PCR and western blotting. All these suggested that Survivin should be very important in the development of osteosarcoma and Survivin blockaded by using antisense pEGFP-C1-Survivin could markedly inhibit the proliferation and invasion of osteosarcoma cells line MG-63, partially reversed their malignant phenotype. Targeting Survivin might be a promising option in the treatment of osteosarcoma.
Keywords: Osteosarcoma, Survivin, Apoptosis.
1These authors contributed equally to this manuscript.
Osteosarcoma is the most frequent primary malignant bone tumor and occurs mainly in children and adolescent (Klein and Siegal, 2006). It is an extremely destructive malignancy that most commonly arises in the long bones (DuBois and Demetri, 2007). Limited improvements had been got by using conventional methods including surgery, radiotherapy and chemotherapy in the past two decades (Lee et al., 2008). Despite the successful use of neoadjuvant chemotherapy in the treatment of osteosarcoma, many patients who have got osteosarcoma remain resistant to treatment due to rapid progression, metastasis, and tendency to chemotherapy resistance (Chou et al., 2005; Lee et al., 2004; Bacci et al., 2007). Gene therapy as a new method to treat tumors has been introduced to osteosarcoma for a few years and has got great achievements (Kishida et al., 2007; Cho et al., 2007). Therapeutic strategies using targeted block the expression of some oncogene may be an effective way to the treatment of osteosarcoma (Lamoureux et al., 2007; Ganjavi et al., 2006; Kersting et al., 2007).
Survivin is a member of the inhibitors of apoptosis (IAP) gene family which is recently described and plays an important role in the inhibition of apoptosis and control of cell division (Ambrosini et al., 1997; Troeger et al., 2007; Stauber et al., 2007; Carelli et al., 2007). It deserves attention as a selective target for cancer therapy because it is highly expressed in most malignancies and embryonic tissues but is undetectable or expressed at a very low level in normal adult tissues (Tanabe et al., 2004; Yamashita et al., 2007; Gazzaniga et al., 2003; Cohen et al., 2003; Gordon et al., 2007). Some studies have shown that Survivin is up regulated in osteosarcoma which indicates a poor prognosis and increased risk of metastasis (Wang et al., 2006; Trieb et al., 2003; Osaka et al., 2007). Thus, Survivin may involve in the development of osteosarcoma and therefore may be a useful target for the therapy of osteosarcoma.
As discussed before, we suppose that Survivin blockade may reduce the proliferation and invasion of osteosarcoma cells. Several studies reported that Survivin knockdown by using antisense RNA, shRNA or other methods could increase the apoptosis rate of many cancer cells (Paduano et al., 2006; Ma et al., 2005; Pratt et al., 2006; Ai et al., 2006; Zhou et al., 2004; Chao et al., 2004). But there is still little report that whether Survivin down regulation could induce the apoptosis of osteosarcoma cells. Therefore, the purpose of this study was designed to observe the effects of antisense Survivin plasmid on the proliferation, apoptosis, migration and invasion of osteosarcoma cells in vitro by using MTT, Flow cytometry and Transwell invasion assay. Furthermore, we detected the changes of the expression of Survivin in osteosarcoma cells by RT-PCR and western blot to investigate the effects of antisense Survivin plasmid on gene expression.
2 Materials and methods
2.1 Cell line and culture conditions
Human osteosarcoma cell line MG-63 was obtained from American Type Culture Collection (ATCC). Cells were cultured in the DMEM complete medium supplemented with 2
2.2 Construction of antisense Survivin plasmids
Survivin cDNA was cloned from a cDNA pool derived from the human osteosarcoma cell lines MG-63 by reverse transcription polymerase chain reaction (RT-PCR), which was performed by using the following primers: sense, 5′-GGA TCC GCA TGG GTG CCC CGA CGT TG-3′, and antisense, 5′-GAA TTC GCT CCG GCC AGA GGC CTC AA-3′, containing BamHI and EcoRI restriction sites, respectively (underlined sequences). The 459
2.3 Transfection of cells with antisense pEGFP-C1-Survivin
Twenty-four hours before transfection, 1.5–2
2.4 Measurement of cell growth by MTT
The growth inhibition rate of MG-63 cells was measured by Methyl thiazolyl tetrazolium (MTT) assay. Cells were plated onto 96-well plates at a density of 5000 cells per well and divided into different groups as described before. After transfected by antisense pEGFP-C1-Survivin for 6
2.5 Apoptosis assay
MG-63 cells were trypsinized and collected after pre-treatment for 48
2.6 Detecting the mRNA expression of Survivin by reverse transcription-PCR
To detect the change of the mRNA expression of Survivin after the treatment of Survivin blockage by antisense pEGFP-C1-Survivin, RT-PCR was performed using a one-step RT-PCR kit (Life Technologies, USA) according to the manufacturer's instructions. After 48
2.7 Measurement of Survivin protein by western blotting
2.8 Migration and invasion assay
A transwell invasion assay was used to detect the invasive property of MG-63 cells' migration. After pre-treatment for 48
2.9 Statistical analysis
All experiments were repeated at least three times. Results were expressed as means
3.1 Effects of antisense pEGFP-C1-Survivin on MG-63 cells' proliferation
MG-63 cells' proliferation was detected by Methyl thiazolyl tetrazolium (MTT) after pre-treatment as described before. As shown in Fig. 1A, notable changes were observed 48
Effects of antisense pEGFP-C1-Survivin on cell proliferation and apoptosis. A. MG-63 cells were transfected by antisense pEGFP-C1-Survivin for 24
3.2 Effects of antisense pEGFP-C1-Survivin on MG-63 cells' apoptosis
It was reported that Survivin involved in cell proliferation, growth, anti-apoptosis, and tumorigenesis. Survivin has been shown highly expression in osteosarcoma (Wang et al., 2006; Trieb et al., 2003; Osaka et al., 2007). To further verify the effects of antisense pEGFP-C1-Survivin on cell apoptosis, flow cytometry analysis was used. As shown in Fig. 1B, we found that apoptosis was induced in MG-63 cells after transfected with antisense pEGFP-C1-Survivin (P
3.3 Down-regulating effects of antisense pEGFP-C1-Survivin on Survivin mRNA and protein
To observe the Survivin blockaded by antisense pEGFP-C1-Survivin, the mRNA and protein expression of Survivin were detected by using RT-PCR and western blotting. In our results, we found in Fig. 2 that the mRNA and protein expression of Survivin were decreased significantly in the MG-63 cells treated with antisense pEGFP-C1-Survivin than controls, which suggested that the inhibition effects of MG-63 cells may be induced by the Survivin blockaded.
Expression of Survivin mRNA and protein in human osteosarcoma cells line MG-63 after transfected with antisense pEGFP-C1-Survivin was detected by RT-PCR and western blot. Cells were treated with antisense pEGFP-C1-Survivin for 48
3.4 Effects of antisense EGFP-C1-Survivin on the cell migration and invasion
Migration and invasion are important features of tumor cells. To study the effects of Survivin knocked down by antisense pEGFP-C1-Survivin on the invasive property of MG-63 cells, transwell invasion assay was used. Cells in control groups showed high invasive activity in vitro, whereas the invasive activity of cells in the experiment group treated with antisense pEGFP-C1-Survivin decreased notablely. This result suggested that Survivin might play an important role in the invasion of osteosarcoma cells and targeted inhibition of Survivin by using antisense pEGFP-C1-Survivin could reverse this malignant feature. It means that Survivin might be a useful marker in the therapy of osteosarcoma.
Osteosarcoma is the most common primary malignant neoplasm of the skeleton in children and adolescent. It occurs frequently in the long bones, such as, the distal of femur and the proximal humerus (Kim et al., 2008). Its natural history is characterized by a rapidly progressive course with early metastasis to the lungs. The prognosis for patients with osteosarcoma is very poor due to the early pulmonary metastasis (Graat et al., 2008). The survival rate of patients who got osteosarcoma five years is only 20% by treated with traditionary therapy methods such as surgery, radiotherapy and chemotherapy (Okada et al., 2004).
During the past few years, the survival rate and quality of life of the patients who had osteosarcoma were improved notablely with the development of new-adjuvant chemotherapy (Bacci et al., 2003). But still many patients with osteosarcoma remained resistant to treatment due to rapid progression and metastasis (Kager et al., 2003). How to postpone the progression and metastasis was the criticality for the therapy of osteosarcoma. Gene therapy as a new method to treat tumors has been found to be an effective way to treat cancers by regulating the expression of some oncogenes and factors relative to the development of tumors.
Several studies have reported that Survivin is a novel member of inhibitors of apoptosis (IAPs) family and is expressed during fetal development and in many tumor tissues, but it lacks expression in terminally differentiated adult tissues (LaCasse et al., 1998; Rahman et al., 2006; Ryan et al., 2006). Over expression of Survivin correlates with resistance to chemotherapy and poor prognosis in patients. Recently studies have found that Survivin may play an important role in the development of osteosarcoma (Osaka et al., 2006). Therefore, we suppose that target blocked the expression of Survivin of osteosarcoma may induce the apoptosis of osteosarcoma cells and improve the chemotherapy sensitivity.
Therapeutic strategy using antisense plasmid has been found to be an effective way to down regulate the expression of oncogene and reduce the apoptotic threshold in tumor cells. Several experiments have been done to observe the effects of antisense Survivin plasmid on tumors and have got great achievements (Tu et al., 2003; Kappler et al., 2007). But there is still little research about the effects of antisense Survivin plasmid on osteosarcoma. In this study, we constructed an antisense Survivin eukaryotic expression vector, which was named antisense pEGFP-C1-Survivin. Targeting Survivin by this antisense plasmid was supposed to inhibit the growth and induce the apoptosis of osteosarcoma cells. To confirm this, MTT and flow cytometry assays were used in our study. Cells were divided into four groups, which were cells treated with antisense pEGFP-C1-Survivin, untreated cells, cells treated with liposome alone, and cells treated with control vector pEGFP. As shown in Fig. 1, we found that the inhibition rate and apoptosis rate increased significantly in the MG-63 cells transfected by the antisense pEGFP-C1-Survivin 48
We have known that high levels of Survivin mRNA and protein expression were significantly associated with clinical resistance to chemotherapy and due to the development and progression of osteosarcoma. RT-PCR and western blotting were used to survey whether the mRNA and protein expression of Survivin in osteosarcoma cells could be down regulated by antisense pEGFP-C1-Survivin. As observed in Fig. 2, the Survivin mRNA and protein expression degraded conspicuously when transfected with antisense pEGFP-C1-Survivin than that in the other three groups, which suggested that antisense pEGFP-C1-Survivin produce its killing effects by inhibiting the expression of Survivin.
It was reported that highly expression of Survivin represented the ability of migration and invasion of tumor cells. In the present study, transwell invasion assay was used to detect the changes of invasive property in MG-63 cells after treatment with antisense pEGFP-C1-Survivin. We could see in Fig. 3 that the invasive activity of osteosarcoma cells decreased notablely when the Survivin expression was blockaded. But there were no significantly changes observed in the other groups.
The effect of antisense pEGFP-C1-Survivin on the migrating activity of MG-63 cells was detected by a transwell invasion assay. MG-63 cells were divided into four groups as described. After pre-treatment for 48
These results revealed that targeting Survivin expression using antisense pEGFP-C1-Survivin might be an effective therapy for osteosarcoma. As reported, Survivin knocked down might increase the sensitivity to chemotherapy. Several studies are now under way to test the efficacy of antisense pEGFP-C1-Survivin in combination with cytotoxic chemotherapy on tumor cells in vitro. It is expected that Survivin blockaded may be a useful gene therapy method in the treatment of osteosarcoma.
In conclusion, we suggested that Survivin play an important role in the development of osteosarcoma. The antisense pEGFP-C1-Survivin could efficiently down regulate the expression level of Survivin and induce cell apoptosis in vitro. We conceive that Survivin might be considered as a therapeutic target for the treatment of osteosarcoma, Survivin inhibition in combination with chemotherapy may increase clinical effectiveness of the treatment of osteosarcoma.
We thank Dr Renyun Xia for the help of the experiment. A part of this work was done in the department of orthopedics, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, PR China.
Bacci G, Briccoli, A, Rocca, M, Ferrari, S, Donati, D, Longhi, A. Neoadjuvant chemotherapy for osteosarcoma of the extremities with metastases at presentation: recent experience at the Rizzoli Institute in 57 patients treated with cisplatin, doxorubicin, and a high dose of methotrexate and ifosfamide. Ann Oncol 2003:14:1126-34
Bacci G, Ferrari, S, Mercuri, M, Longhi, A, Fabbri, N, Galletti, S. Neoadjuvant chemotherapy for osteosarcoma of the extremities in patients aged 41–60 years: outcome in 34 cases treated with adriamycin, cisplatinum and ifosfamide between 1984 and 1999. Acta Orthop 2007:78:377-84
Chao JI, Kuo, PC, Hsu, TS. Down-regulation of survivin in nitric oxide-induced cell growth inhibition and apoptosis of the human lung carcinoma cells. J Biol Chem 2004:279:20267-76
Cho HJ, Lee, TS, Park, JB, Park, KK, Choe, JY, Sin, DI. Disulfiram suppresses invasive ability of osteosarcoma cells via the inhibition of MMP-2 and MMP-9 expression. J Biochem Mol Biol 2007:40:1069-76
Chou AJ, Merola, PR, Wexler, LH, Gorlick, RG, Vyas, YM, Healey, JH. Treatment of osteosarcoma at first recurrence after contemporary therapy: the Memorial Sloan-Kettering Cancer Center experience. Cancer 2005:104:2214-21
Cohen C, Lohmann, CM, Cotsonis, G, Lawson, D, Santoianni, R. Survivin expression in ovarian carcinoma: correlation with apoptotic markers and prognosis. Mod Pathol 2003:16:574-83
Ganjavi H, Gee, M, Narendran, A, Parkinson, N, Krishnamoorthy, M, Freedman, MH. Adenovirus-mediated p53 gene therapy in osteosarcoma cell lines: sensitization to cisplatin and doxorubicin. Cancer Gene Ther 2006:13:415-9
Gazzaniga P, Gradilone, A, Giuliani, L, Gandini, O, Silvestri, I, Nofroni, I. Expression and prognostic significance of LIVIN, SURVIVIN and other apoptosis-related genes in the progression of superficial bladder cancer. Ann Oncol 2003:14:85-90
Gordon GJ, Mani, M, Mukhopadhyay, L, Dong, L, Edenfield, HR, Glickman, JN. Expression patterns of inhibitor of apoptosis proteins in malignant pleural mesothelioma. J Pathol 2007:211:447-54
Graat HC, van Beusechem, VW, Schagen, FH, Witlox, MA, Kleinerman, ES, Helder, MN. Intravenous administration of the conditionally replicative adenovirus Ad5-Delta24RGD induces regression of osteosarcoma lung metastases. Mol Cancer 2008:23:9
Kager L, Zoubek, A, Pötschger, U, Kastner, U, Flege, S, Kempf-Bielack, B. Cooperative German-Austrian-Swiss Osteosarcoma Study Group. Primary metastatic osteosarcoma: presentation and outcome of patients treated on neoadjuvant Cooperative Osteosarcoma Study Group protocols. J Clin Oncol 2003:21:2011-8
Kappler M, Rot, S, Taubert, H, Greither, T, Bartel, F, Dellas, K. The effects of knockdown of wild-type survivin, survivin-2B or survivin-delta3 on the radiosensitization in a soft tissue sarcoma cells in vitro under different oxygen conditions. Cancer Gene Ther 2007:14:994-1001
Kersting C, Gebert, C, Agelopoulos, K, Schmidt, H, van Diest, PJ, Juergens, H. Epidermal growth factor receptor expression in high-grade osteosarcomas is associated with a good clinical outcome. Clin Cancer Res 2007:13:2998-3005
Kim MS, Lee, SY, Cho, WH, Song, WS, Koh, JS, Lee, JA. Initial tumor size predicts histologic response and survival in localized osteosarcoma patients. J Surg Oncol 2008:97:456-61
Kishida Y, Yoshikawa, H, Myoui, A. Parthenolide, a natural inhibitor of nuclear factor-kappaB, inhibits lung colonization of murine osteosarcoma cells. Clin Cancer Res 2007:13:59-67
Lamoureux F, Richard, P, Wittrant, Y, Battaglia, S, Pilet, P, Trichet, V. Therapeutic relevance of osteoprotegerin gene therapy in osteosarcoma: blockade of the vicious cycle between tumor cell proliferation and bone resorption. Cancer Res 2007:67:7308-18
Lee RS, Higgs, D, Haddo, O, Pringle, J, Briggs, TW. Osteosarcoma associated with diamond-blackfan anaemia: a case of a child receiving growth hormone therapy. Sarcoma 2004:8:47-9
Lee JA, Kim, MS, Kim, DH, Lim, JS, Yoo, JY, Koh, JS. Relative tumor burden predicts metastasis-free survival in pediatric osteosarcoma. Pediatr Blood Cancer 2008:50:195-200
Okada K, Hasegawa, T, Nishida, J, Ogose, A, Tajino, T, Osanai, T. Osteosarcomas after the age of 50: a clinicopathologic study of 64 cases – an experience in northern Japan. Ann Surg Oncol 2004:11:998-1004
Osaka E, Suzuki, T, Osaka, S, Yoshida, Y, Sugita, H, Asami, S. Survivin expression levels as independent predictors of survival for osteosarcoma patients. J Orthop Res 2007:25:116-21
Paduano F, Villa, R, Pennati, M, Folini, M, Binda, M, Daidone, MG. Silencing of survivin gene by small interfering RNAs produces supra-additive growth suppression in combination with 17-allylamino-17-demethoxygeldanamycin in human prostate cancer cells. Mol Cancer Ther 2006:5:179-86
Pratt MA, Niu, MY, Renart, LI. Regulation of survivin by retinoic acid and its role in paclitaxel-mediated cytotoxicity in MCF-7 breast cancer cells. Apoptosis 2006:11:589-605
Rahman KW, Li, Y, Wang, Z, Sarkar, SH, Sarkar, FH. Gene expression profiling revealed survivin as a target of 3,3′-diindolylmethane-induced cell growth inhibition and apoptosis in breast cancer cells. Cancer Res 2006:66:4952-60
Ryan BM, Konecny, GE, Kahlert, S, Wang, HJ, Untch, M, Meng, G. Survivin expression in breast cancer predicts clinical outcome and is associated with HER2, VEGF, urokinase plasminogen activator and PAI-1. Ann Oncol 2006:17:597-604
Troeger A, Siepermann, M, Escherich, G, Meisel, R, Willers, R, Gudowius, S. Survivin and its prognostic significance in pediatric acute B-cell precursor lymphoblastic leukemia. Haematologica 2007:92:1043-50
Tu SP, Jiang, XH, Lin, MC, Cui, JT, Yang, Y, Lum, CT. Suppression of survivin expression inhibits in vivo tumorigenicity and angiogenesis in gastric cancer. Cancer Res 2003:63:7724-32
Zhou J, O'brate, A, Zelnak, A, Giannakakou, P. Survivin deregulation in beta-tubulin mutant ovarian cancer cells underlies their compromised mitotic response to taxol. Cancer Res 2004:64:8708-14
Received 28 June 2008/22 August 2008; accepted 13 October 2008doi:10.1016/j.cellbi.2008.10.013